

A [^3H]amine congener of 1,3-dipropyl-8-phenylxanthine

A new radioligand for A2 adenosine receptors of human platelets

Dieter Ukena, Kenneth A. Jacobson*, Kenneth L. Kirk* and John W. Daly

Laboratory of Bioorganic Chemistry and *Laboratory of Chemistry, National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20205, USA

Received 21 February 1986

A xanthine amine congener (XAC), an amine-functionalized derivative of 1,3-dipropyl-8-phenylxanthine, is an antagonist ligand for A2 adenosine receptors of human platelets. XAC inhibited 5'-N-ethylcarboxamido-adenosine (NECA)-induced stimulation of adenylate cyclase activity with a K_B of 24 nM. [^3H]XAC exhibits saturable, specific binding with a K_d of 12 nM and a B_{max} of 1.1 pmol/mg protein at 37°C. [^3H]XAC binding in platelets is the first example of labeling of A2 adenosine receptors in which the potencies of adenosine agonists and antagonists in inhibiting binding are commensurate with their potencies at these receptors in functional studies. Furthermore, [^3H]XAC is the first antagonist radioligand with high affinity at A2 adenosine receptors.

Adenosine receptor Platelet Xanthine

1. INTRODUCTION

A variety of radioligands have been developed for the A1 adenosine receptors that mediate inhibition of adenylate cyclase: such ligands have been extensively used in investigation of A1 receptors (reviews [1,2]). Radioligands for the A2 adenosine receptors that mediate stimulation of adenylate cyclase have not proven entirely satisfactory. In striatal membranes, 5'-N-[^3H]ethylcarboxamido-adenosine ([^3H]NECA) appears to bind to both A1 and A2 adenosine receptors, and strategies for elimination of A1 receptor binding have been developed [3]. In peripheral tissues, binding studies with [^3H]NECA have not been proven satisfactory, particularly with respect to structure-activity profiles for adenosine antagonism by adenosine analogs and xanthines [2].

1,3-[^3H]Diethyl-8-phenylxanthine ([^3H]DPX) has been the only antagonist radioligand for the study of adenosine receptors [4]. Based on a binding study with guinea pig brain, the suggestion

has been made that [^3H]DPX may label A2 adenosine receptors [4]. This appears unlikely, since N^6 -substituted adenosine analogs were very weak and compounds without intrinsic activity at adenosine receptors were relatively potent in competing for [^3H]DPX binding [4]. Thus, a direct characterization of A2 adenosine receptors with an antagonist radioligand has still not been achieved, and even for A1 receptors [^3H]DPX is not entirely satisfactory.

A 'functionalized congener' approach to adenosine receptor ligands has been developed [5,6]. In this approach 1,3-dipropyl-8-phenylxanthine was modified to provide a *p*-carboxymethoxy function for covalent attachment to amines, amino acids and oligopeptides [5,6]. One potent analog, a 1,3-dipropylxanthine amine congener (XAC), has been tritiated to high specific activity (103 Ci/mmol). [^3H]XAC binds with K_d values of 0.17 and 1.2 nM to A1 adenosine receptors of calf and rat brain, respectively [7]. It represents the most satisfactory antagonist radioligand for the study of A1 adenosine recep-

tors. Here, [^3H]XAC was used as a radioligand for the A2 adenosine receptors in human platelets.

2. MATERIALS AND METHODS

Human platelet membranes were prepared as in [8]. Adenylate cyclase was assayed essentially as described [8]. Briefly stated, the medium contained 0.1 mM [α - ^{32}P]ATP (0.3 $\mu\text{Ci}/\text{tube}$), 1 μM GTP, 1 mM MgCl_2 , 0.1 mM cyclic AMP, 1 $\mu\text{g}/\text{ml}$ adenosine deaminase, 0.1 mM rolipram (4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidinone, ZK 62,711), 1 mM EGTA, 5 mM creatine phosphate as the Tris salt, 0.4 $\mu\text{g}/\text{ml}$ creatine kinase, 2 mg/ml bovine serum albumin and 50 mM Tris-HCl, pH 7.4, in a total volume of 100 μl . Incubations were initiated by the addition of 5–15 μg membrane protein and were conducted for 10 min at 37°C. Reactions were stopped by the addition of 0.4 ml of 125 mM zinc acetate and 0.5 ml of 144 mM Na_2CO_3 . Cyclic AMP was purified as described in [8].

The binding of [^3H]XAC to human platelet membranes was measured in a total volume of 1 ml containing 50 mM Tris-HCl, pH 7.4, 0.1 $\mu\text{g}/\text{ml}$ adenosine deaminase and approx. 100–200 μg membrane protein. In competition experiments the radioligand was present in a final concentration of 1 nM. Other substances were added as indicated. Incubation was carried out at 37°C for 90 min. All assays were done in triplicate. Bound and free radioligand were separated by filtering the assay volume through Whatman GF/B glass-fiber filters that had been treated with 0.3% polyethylene imine for 90 min as described by Bruns et al. [9]. The filters were washed twice with 5 ml ice-cold incubation buffer. Nonspecific binding of [^3H]XAC was determined in the presence of 5 mM theophylline.

Synthesis and purification of ^3H -labeled 8-[[[(2 - aminoethyl)amino]carbonyl)methyl]oxy] - phenyl]-1,3-dipropylxanthine ([^3H]XAC) with a specific activity of 103 Ci/mmol are described elsewhere [7]. Other compounds were synthesized




Fig.1. Stimulation of adenylate cyclase activity of human platelet membranes by NECA in the absence (●—●) and presence of XAC (2 nM, ■—■; 20 nM, ▲—▲; 200 nM, ◆—◆). Adenylate cyclase activity was determined at 37°C for 90 min. Right: Schild plot of the same data with the concentration ratio (CR) of the EC $_{50}$ values for NECA in the presence and absence of XAC vs the XAC concentration (slope, 1.05; $r = 0.9993$). EC $_{50}$ values for NECA: 0.255 μM in the absence and 0.27, 0.46 and 2.29 μM in the presence of 2, 20 and 200 nM XAC, respectively. Values are means of a typical experiment done in triplicate.

as in [5–7]. Materials and chemicals were from standard sources as described [5,7].

EC_{50} and IC_{50} values were obtained from concentration-response curves by linear regression after logit-log transformation. IC_{50} values were transformed into K_i values according to Cheng and Prusoff [10]. Slope factors of inhibition curves (n_H) were calculated from indirect Hill plots.

3. RESULTS

The potency of XAC as an antagonist at A2 adenosine receptors of human platelets was determined vs the NECA-stimulated adenylate cyclase activity in membranes. In human platelets, NECA has been shown to be a potent agonist at A2 receptors that mediate inhibition of aggregation via an activation of adenylate cyclase [8,11]. NECA stimulates adenylate cyclase activity about 4-fold over basal values with an EC_{50} of $0.255 \mu M$ (fig.1). XAC shifted the concentration-response curve of NECA in a concentration-dependent manner to the right without changing the slope or the degree of stimulation by NECA (fig.1) suggesting com-

petitive antagonism. The dissociation constant, K_B , for XAC, calculated from the Schild plot, was 24 nM as shown in the right panel of fig.1. The slope of the line near unity confirms the competitive antagonism between NECA and XAC.

Radioligand binding experiments with tritiated XAC were performed at $37^\circ C$. A typical saturation experiment is shown in fig.2. Specific [3H]XAC binding is saturable with a binding capacity (B_{max}) of 1.1 pmol/mg protein. The Scatchard plot of the data is linear, indicating a homogeneous population of noncooperative binding sites with a K_d of 12 nM. Nonspecific binding determined in the presence of 5 mM theophylline was very high and amounted to about 75% of total binding at K_d . The same amount of nonspecific binding was obtained in the presence of 1 mM NECA. At $4^\circ C$, similar K_d and B_{max} values were obtained, and nonspecific binding amounted to 60% of total binding at K_d (not shown).

Other known agonists and antagonists at adenosine receptors competitively displaced specific [3H]XAC binding to platelet membranes (fig.3, table 1). The competition curves are




Fig.2. Saturation of [3H]XAC binding to human platelet membranes. Specific (●—●) and nonspecific (○—○) binding were determined for 90 min at $37^\circ C$. Values are means of a typical experiment done in triplicate. Right: Scatchard plot of the same data. K_d , 12 nM; B_{max} , 1.1 pmol/mg protein.




Fig.3. Competition for [3 H]XAC binding to human platelet membranes. Binding of 1 nM [3 H]XAC was measured for 90 min at 37°C. Slope factors: 0.94 for XAC (●—●), 0.91 for NECA (◆—◆), 0.97 for 8-phenyltheophylline (■—■), 0.99 for R-PIA (▼—▼) and 0.91 for theophylline (▲—▲). Values are means of a typical experiment done in triplicate.

Table 1

Competition for [3 H]XAC binding to human platelet membranes

Compound	K_i (μ M)
1,3-Dipropyl-8-($H_2N(CH_2)_2NHCOCH_2$ -O-phenyl)xanthine (XAC)	0.017
1,3-Diethyl-8-phenylxanthine (DPX)	0.19
5'-N-Ethylcarboxamidoadenosine	0.33
1,3-Dipropyl-8-phenylxanthine	1.0
8-Phenyltheophylline	1.7
1,3-Dipropyl-8-(p -HO $_2$ CCH $_2$ O-phenyl)-xanthine (XCC)	1.8
1,3-Dipropyl-8-(p -sulphophenyl)xanthine	2.4
N^6 -R-Phenylisopropyladenosine (R-PIA)	5.7
8-(p -Sulphophenyl)theophylline	7.2
Theophylline	29
Caffeine	51
ATP	> 100 (25%)
Adenine	> 100 (19%)
Inosine	> 100 (1%)

Binding of 1 nM [3 H]XAC was measured for 90 min at 37°C. K_i values are means of 2 experiments done in triplicate. For K_i values above 100 μ M, the percentage inhibition of [3 H]XAC binding at 100 μ M is given in parentheses

monophasic with slope factors near unity. XAC itself was the most potent inhibitor of [3 H]XAC binding with a K_i value of 17 nM. This value is in good agreement with the K_d values derived from the saturation experiments with [3 H]XAC. DPX was about 10-fold less potent than XAC, but about 5-fold more potent than 1,3-dipropyl-8-phenylxanthine. The carboxylic acid congener (XCC) and the p -sulfo derivative of the latter compound were as potent as 8-phenyltheophylline in competing for [3 H]XAC-binding sites. Theophylline and caffeine have K_i values of 29 and 51 μ M, respectively, whereas ATP, adenine and inosine were inactive at [3 H]XAC-binding sites. The agonist NECA has a K_i of 0.33 μ M, which is in good agreement with the EC_{50} value for the stimulation of adenylate cyclase activity in these membranes. R-PIA was about 20-fold less potent than NECA as an inhibitor of [3 H]XAC binding and is 10-fold less potent than NECA in stimulation of adenylate cyclase activity.

4. DISCUSSION

Several attempts have been made to characterize A2 adenosine receptors in radioligand-binding studies. [3 H]NECA has been used often as an agonist radioligand for A2 adenosine receptors [12–15]. However, the binding characteristics of

[³H]NECA to membranes containing only A2 receptors are not fully consonant with that expected of A2 receptors, since *N*⁶-substituted adenosine analogs, which do activate adenylate cyclase in these membranes, are weak or inactive as antagonists of [³H]NECA binding [12–15]. Furthermore, antagonists like DPX and 8-phenyltheophylline, which are potent inhibitors of NECA-induced cyclic AMP accumulation or NECA-stimulated adenylate cyclase activity, did not compete for [³H]NECA-binding sites [13,15,16]. At least in peripheral tissues, therefore, the results with [³H]NECA have not been satisfactory.

The antagonist radioligand [³H]DPX has been reported to label A2 adenosine receptors in guinea pig brain membranes [4]. Again, several discrepancies in the structure-activity profile were observed. Compounds that are neither agonists nor antagonists at A2 receptors in brain, such as 8-bromoadenosine, competed for [³H]DPX binding, whereas the potent receptor against 5'-*N*-cyclopropylcarboxamidoadenosine was a very weak displacer of [³H]DPX binding [4]. Therefore, the nature of the [³H]DPX-binding sites in guinea pig brain remains unclear [2,4]. In addition, [³H]DPX has several shortcomings: it has only a low affinity for adenosine receptors in most tissues and a relatively low specific activity.

Recently, we have introduced a tritiated xanthine amine congener ([³H]XAC) as new antagonist radioligand for adenosine receptors [7]. [³H]XAC overcomes many of the limitations of the [³H]DPX radioligand. The *K*_d value for [³H]XAC binding to A1 receptors in rat brain membranes is 50-fold lower than that of [³H]DPX [7], and the specific activity is 8-fold higher than that of [³H]DPX. In addition to the usefulness of [³H]XAC as a radioligand for A1 receptors, the present study demonstrates that [³H]XAC is also useful for labeling of A2 adenosine receptors. XAC has a *K*_B value of 24 nM for the antagonism of NECA-induced stimulation of adenylate cyclase activity in human platelet membranes. Thus, XAC is the most potent xanthine antagonist at A2 adenosine receptors yet reported.

In platelet membranes, [³H]XAC exhibits saturable, specific binding with a *K*_d of 12 nM, which is about 2-fold lower than the *K*_B determined in cyclase experiments. The *K*_i value of

XAC for inhibition of [³H]XAC binding is in good agreement with the *K*_d value from the saturation experiments and the *K*_B value from the cyclase experiments. Several xanthines compete for [³H]XAC binding in the known order of potency. The *K*_i values of these xanthines are in good agreement with the *K*_B values for antagonism of NECA-induced adenylate cyclase stimulation in the same membrane preparation [16,17]. Only the *K*_i value for theophylline is 2–3-fold higher than that determined in cyclase and aggregation studies [16,17]. The potencies of the adenosine agonists NECA and R-PIA in inhibiting [³H]XAC binding are similar to the *EC*₅₀ values for the stimulation of adenylate cyclase activity [8]. In contrast to the results with [³H]NECA binding in platelets [14], therefore, the profile of agonists and antagonists for the inhibition of [³H]XAC binding is commensurate with the data from functional studies like adenylate cyclase and aggregation [8,16,17].

A relative high level of filter binding was evident with [³H]XAC. The problem was solved in part by pretreatment of the glass-fiber filters with polyethylene imine according to Bruns et al. [9]. The filter binding is the main reason for the high nonspecific binding as shown in the saturation experiment (fig.2). A further reduction in filter binding should permit the use of [³H]XAC for more detailed studies on A2 adenosine receptors in other tissues.

ACKNOWLEDGEMENT

One of the authors (D.U.) is on leave from the Pharmakologisches Institut der Universität Heidelberg with support of the Deutsche Forschungsgemeinschaft (Uk 4/1-1).

REFERENCES

- [1] Daly, J.W. (1982) *J. Med. Chem.* 25, 197–207.
- [2] Daly, J.W. (1985) in: *Adenosine: Receptors and Modulation of Cell Function* (Stefanovich, V. et al. eds) pp.31–46, IRL Press, Washington, DC.
- [3] Yeung, S.-M.H. and Green, R.D. (1984) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 325, 218–225.
- [4] Bruns, R.F., Daly, J.W. and Snyder, S.H. (1980) *Proc. Natl. Acad. Sci. USA* 77, 5547–5551.
- [5] Jacobson, K.A., Kirk, K.L., Padgett, W.L. and Daly, J.W. (1985) *J. Med. Chem.* 28, 1334–1340.

- [6] Jacobson, K.A., Kirk, K.L., Padgett, W.L. and Daly, J.W. (1986) *Mol. Pharmacol.*, in press.
- [7] Jacobson, K.A., Ukena, D., Kirk, K.L. and Daly, J.W. (1986) *Proc. Natl. Acad. Sci. USA*, in press.
- [8] Ukena, D., Boehme, E. and Schwabe, U. (1984) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 327, 36–42.
- [9] Bruns, R.F., Lawson-Wendling, K. and Pugsley, T.A. (1983) *Anal. Biochem.* 132, 74–81.
- [10] Cheng, Y.C. and Prusoff, W.H. (1973) *Biochem. Pharmacol.* 22, 3099–3108.
- [11] Cusack, N.J. and Hourani, S.M.O. (1981) *Br. J. Pharmacol.* 72, 443–447.
- [12] Schütz, W., Tüisl, E. and Kraupp, O. (1982) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 319, 34–39.
- [13] Schütz, W., Steuerer, G. and Tüisl, E. (1982) *Eur. J. Pharmacol.* 85, 177–184.
- [14] Hüttemann, E., Ukena, D., Lenschow, V. and Schwabe, U. (1984) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 325, 226–233.
- [15] Ukena, D., Schirren, C.G., Klotz, K.-N. and Schwabe, U. (1985) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 331, 310–316.
- [16] Ukena, D., Boehme, E. and Schwabe, U. (1985) in: *Adenosine: Receptors and Modulation of Cell Function* (Stefanovich, V. et al. eds) pp.343–349, IRL Press, Washington, DC.
- [17] Ukena, D., Daly, J.W., Kirk, K.L. and Jacobson, K.A. (1986) *Life Sci.* 38, 797–807.